CompleGen Announces Successful Delivery of Its XenoGene Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
CompleGen's XenoGene technology uses the power of genetics to identify allosteric inhibitors that are selective for specific protein targets.
"We are very pleased to be working with Boehringer Ingelheim to open pathways for therapeutics that have proved to be elusive previously," commented Pauline Gee, CompleGen's VP Business Development.
Seattle, WA and Ridgefield, CT [January 17, 2012]
SEATTLE, Jan. 17, 2012 PRNewswire -- CompleGen, Inc. announced today that they have executed a non-exclusive services agreement regarding CompleGen's XenoGene technology. Boehringer Ingelheim's discovery team will apply the technology to explore targets that are not easily accessible by other discovery platforms.
CompleGen is a drug discovery company that uses its proprietary discovery platform, XenoGene
technology to identify and develop selective inhibitors for difficult targets.
With its small molecule library, CompleGen has identified potent
allosteric inhibitors for targets where other discovery platforms have failed.
These allosteric inhibitors have been shown to be efficacious and well tolerated in animals.
Pauline Gee, PhD
Vice President, Business Development
1124 Columbia Street, Suite 662
Seattle, WA 98104